Salix Pharmaceuticals, Ltd.  

(Public, NASDAQ:SLXP)   Watch this stock  
Find more results for SLXP
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 86.00 - 172.98
Open     -
Vol / Avg. 0.00/4.96M
Mkt cap 10.94B
P/E     -
Div/yield     -
EPS -6.51
Shares 64.25M
Beta 0.94
Inst. own 112%

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2134.34% -36.60%
Operating margin -3141.96% -43.24%
EBITD margin - -2.16%
Return on average assets -25.83% -11.78%
Return on average equity -305.24% -85.82%
Employees 1,000 -
CDP Score - -


8510 Colonnade Center Dr
RALEIGH, NC 27615-3050
United States - Map
+1-919-8621000 (Phone)
+1-919-8621095 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.